webinar register page

Webinar banner
“Fireside Chat” with CEO Allen W. Davidoff, PhD | Exciting developments in new therapies for progressive kidney diseases
XORTX Therapeutics, Inc. is a drug-based biotechnology company focused on developing novel therapies to address the high unmet medical needs of those with progressive severe kidney diseases.

The market for such therapies globally is massive, and growing with an anticipated annual growth rate of 12.7% through 2028 since 2020, in part due to complications caused by Covid-19.

Problem: For patients with progressive kidney disease, only one FDA-approved therapy is currently available which is expensive.

Solution: XORTX is stepping into that void in the marketplace with a novel approach to fighting progressive kidney disease utilizing an existing drug, the xanthine oxidase inhibitor, and uric acid lowering agent oxypurinol.

What is in for you- In this “Fireside Chat”, we’ll have the best from the industry speaking on the panel that is Dr. Davidoff who will update these developments and more and answer questions from investors and potential investors.

Jun 22, 2022 11:00 AM in Eastern Time (US and Canada)

Webinar is over, you cannot register now. If you have any questions, please contact Webinar host: .